Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease
Robert Lenz(Amgen (United States)), Mario Saltarelli(AbbVie (United States)), Yili Pritchett(Abbott (United Kingdom)), Daniel A. Llano(Carle Foundation Hospital), Carl Sadowsky(Nova Southeastern University), Walid Abi‐Saab(Novartis (Switzerland)), Shu Han(Sichuan University), Donald A. Berry(Berry & Associates (United States)), Scott Berry(Queen's University)
Cited by 28
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980